Publication | Closed Access

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Interim AnalysisSurgical OncologyOncologyPembrolizumab Versus PlaceboImmunologyClinical TrialsImmune Checkpoint InhibitorCancer TreatmentAdjuvant TherapyMedicineLung Cancer